スイスのMSコホートにおけるB細胞減少治療を開始した患者の治療持続性と臨床結果に関する編集者への手紙
Joaquín Borrás-Blasco1, Alejandro Valcuende-Rosique2, Silvia Cornejo-Uixeda1
1Pharmacy Department, Sagunto Hospital, Sagunto, Spain.
Multiple sclerosis journal - experimental, translational and clinical
|September 2, 2025
まとめ
No abstract available in PubMed .
関連する概念動画
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...